217 related articles for article (PubMed ID: 32340173)
1. Drug Conjugates for Targeting Eph Receptors in Glioblastoma.
Sharma P; Roberts C; Herpai D; Fokt ID; Priebe W; Debinski W
Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32340173
[TBL] [Abstract][Full Text] [Related]
2. Multireceptor targeting of glioblastoma.
Sharma P; Sonawane P; Herpai D; D'Agostino R; Rossmeisl J; Tatter S; Debinski W
Neurooncol Adv; 2020; 2(1):vdaa107. PubMed ID: 33150335
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of Eph receptors in glioblastoma.
Ferluga S; Tomé CM; Herpai DM; D'Agostino R; Debinski W
Oncotarget; 2016 Sep; 7(37):59860-59876. PubMed ID: 27494882
[TBL] [Abstract][Full Text] [Related]
4. Receptor-Targeted Glial Brain Tumor Therapies.
Sharma P; Debinski W
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30366424
[TBL] [Abstract][Full Text] [Related]
5. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes.
Chen Z; Yuan SJ; Li K; Zhang Q; Li TF; An HC; Xu HZ; Yue Y; Han M; Xu YH; Komatsu N; Zhao L; Chen X
J Control Release; 2020 Apr; 320():469-483. PubMed ID: 31987922
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
9. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors.
Debinski W; Dickinson P; Rossmeisl JH; Robertson J; Gibo DM
PLoS One; 2013; 8(10):e77719. PubMed ID: 24147065
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.
Li TF; Xu YH; Li K; Wang C; Liu X; Yue Y; Chen Z; Yuan SJ; Wen Y; Zhang Q; Han M; Komatsu N; Zhao L; Chen X
Acta Biomater; 2019 Mar; 86():381-394. PubMed ID: 30654213
[TBL] [Abstract][Full Text] [Related]
11. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
12. Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma.
Malfanti A; Catania G; Degros Q; Wang M; Bausart M; Préat V
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057020
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.
Dragojevic S; Mackey R; Raucher D
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
[TBL] [Abstract][Full Text] [Related]
15. Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.
Haas B; Ciftcioglu J; Jermar S; Weickhardt S; Eckstein N; Kaina B
J Cancer Res Clin Oncol; 2021 Mar; 147(3):779-792. PubMed ID: 33315125
[TBL] [Abstract][Full Text] [Related]
16. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
17. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
18. Functionalisation of extracellular vesicles with cyclic-RGDyC potentially for glioblastoma targeted intracellular drug delivery.
Geng T; Leung E; Chamley LW; Wu Z
Biomater Adv; 2023 Jun; 149():213388. PubMed ID: 37003022
[TBL] [Abstract][Full Text] [Related]
19. Distinctive Structure of the EphA3/Ephrin-A5 Complex Reveals a Dual Mode of Eph Receptor Interaction for Ephrin-A5.
Forse GJ; Uson ML; Nasertorabi F; Kolatkar A; Lamberto I; Pasquale EB; Kuhn P
PLoS One; 2015; 10(5):e0127081. PubMed ID: 25993310
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
